Vera Therapeutics appoints new CMO and CDO; prior CMO departed

Vera Therapeutics, Inc.

Dr. Celia Lin separated as CMO effective Jan 3, 2024; received target 2023 bonus and severance.
Dr. Robert Brenner appointed CMO effective Jan 3, 2024; brings 25+ yrs nephrology and biotech experience.
William D. Turner appointed CDO effective immediately; led drug development, NDA/MAA filings at Sierra and Aimmune.
Both execs to support atacicept Phase 3 trial in IgA nephropathy and pipeline development.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Celia Lin

Chief Medical Officer

VERA · Vera Therapeutics, Inc.

Effective: 2024-01-03
Successor: Robert M. Brenner
Filed: January 8, 2024, 6:59 PM ET

On January 8, 2024, Vera Therapeutics, Inc. (the "Company") announced that Celia Lin, M.D., the Company’s Chief Medical Officer, had separated from the Company effective January 3, 2024 (the "Separation Date").

Appointed

Robert M. Brenner

Chief Medical Officer

VERA · Vera Therapeutics, Inc.

Effective: 2024-01-03
Filed: January 8, 2024, 6:59 PM ET

The Company appointed Dr. Robert M. Brenner, M.D., to succeed Dr. Lin as the Company’s Chief Medical Officer, effective January 3, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Celia Lin departed as Chief Medical Officer at Vera Therapeutics, Inc..

Action: separated
Role: Chief Medical Officer

Exact text from the filing

On January 8, 2024, Vera Therapeutics, Inc. (the "Company") announced that Celia Lin, M.D., the Company’s Chief Medical Officer, had separated from the Company effective January 3, 2024 (the "Separation Date").

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert M. Brenner was appointed as Chief Medical Officer at Vera Therapeutics, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

The Company appointed Dr. Robert M. Brenner, M.D., to succeed Dr. Lin as the Company’s Chief Medical Officer, effective January 3, 2024.

View on SEC.gov

Vera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-003931

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.